Loading…
Loading…
EQUITY / NASDAQ · XNCM
Monopar Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗77.97 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 77.97 USD · Volume 107,633
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -6,644,663 USD | — | — |
| Net income | -5,313,300 USD | — | — |
| Cash and cash equivalents | 52,757,766 USD | — | — |
| Total liabilities | 4,123,859 USD | — | — |
| Total equity | 130,854,970 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2024 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 52,757,766 USD | — | — | 61,833,552 USD | 61,833,552 USD | 127,677,360 USD | — | — |
| Net incomeIncome statement | -5,313,300 USD | -9,206,350 USD | -3,893,050 USD | — | -13,716,894 USD | -3,437,601 USD | -8,516,099 USD | — |
| Operating profitIncome statement | -6,644,663 USD | -11,869,916 USD | — | — | -16,704,415 USD | -4,093,074 USD | -10,549,187 USD | — |
| Total assetsBalance sheet | 134,978,829 USD | — | — | 140,717,709 USD | 140,717,709 USD | 144,197,278 USD | — | — |
| Total equityBalance sheet | 130,854,970 USD | — | 135,394,412 USD | 137,827,553 USD | 137,827,553 USD | 141,557,848 USD | — | — |
| Total liabilitiesBalance sheet | 4,123,859 USD | — | — | 2,890,156 USD | 2,890,156 USD | 2,639,430 USD | — | — |
| Financing cash flowCash flow statement | — | -847,592 USD | — | — | 91,574,402 USD | — | 91,959,082 USD | — |
| Investing cash flowCash flow statement | — | -1,468,080 USD | — | — | -63,453,114 USD | — | -1,264,561 USD | — |
| Operating cash flowCash flow statement | — | -6,721,343 USD | — | — | -12,201,291 USD | — | -8,831,219 USD | — |
| RevenueIncome statement | — | 0 USD | — | — | 0 USD | — | — | 0 USD |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.